The Medicines Transparency Alliance (MeTA) was created in recognition of
the key importance of access to medicines.These documents report on:
- Establishing a framework for MeTA in pilot countries; gaining
government commitment and establishing sectoral and national
- Delivering against the MeTA objectives in countries; progress towards
data identification, disclosure, changes in practice and logframe
- The genesis of MeTA
- International governance; the management board, advisory group,
secretariat, private sector and civil society.
- The MeTA hypotheses
The future of MeTA is examined including:
- Funding mechanisms and identification of new funders
- Governance arrangements
- Identification of new countries
- Whether to continue support to existing countries
- The design and identification of the international secretariat
- What might be different?
Ollier, E.; Gittins, N.; Collins, T.; Mubangizi, P.; Waddington, C.; Whitaker, D. Assignment Report: Evaluation of the Medicines Transparency Alliance Phase 1, 2008-2010. HDRC, UK (2010) 126 pp.